Overview

Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and Truvada

Status:
Completed

Trial end date:
2008-11-01

Target enrollment:

Participant gender:

Summary

the trial assessed the pharmacokinetics and long term plasma exposure of the following antiretrovirals: atazanavir when combined to ritonavir and the tenofovir/emtricitabine fixed-dose combination. All drugs will be delivered in MEMS electronic device to monitor dosing history.

Phase:

Phase 2

Details

Lead Sponsor:

French National Agency for Research on AIDS and Viral Hepatitis

Collaborators:

Bristol-Myers Squibb
Gilead Sciences

Treatments:

Atazanavir Sulfate
Emtricitabine
Ritonavir
Tenofovir